Susan Pandya: Throughout my career I’ve aimed to make a difference for patients
Susan Pandya, Global Head of Oncology Clinical Development Late Stage and LCM at Servier Pharmaceuticals, shared MOMA Therapeutics’s post on LinkedIn:
“Throughout my career I’ve aimed to make a difference for patients. From my time as a clinician, to the work I’ve been able to do in industry, the goal has always been to advance novel treatments for patients who need them.
I’m excited to announce that I’m taking another step towards advancing this goal by joining as an independent member of MOMA Therapeutics Board of Directors. I look forward to working with the rest of the board and MOMA’s management team to help advance this portfolio and potentially demonstrate transformative benefit for patients!”
Quoting MOMA Therapeutics’s post on LinkedIn:
“Today, we’re pleased to share Susan Pandya’s appointment as an independent member of our board of directors. Dr. Pandya currently serves as vice president, clinical development and global head of late-stage oncology at Servier Pharmaceuticals. She brings nearly 20 years of oncology drug development experience in both academic and industry settings. Welcome to the MOMA team!
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023